Methods for reducing oxidative damage

• US 7,550,439 B2
• Filed: 01/21/2005
• Issued: 06/23/2009
• Est. Priority Date: 01/23/2004
• Status: Active Grant

• Current Assignee: Cornell Research Foundation Incorporated (Cornell University)
• Original Assignee: Cornell Research Foundation Incorporated (Cornell University)
• Inventors: Szeto, Hazel H.
• Primary Examiner(s): Gupta; Anish
• Application Number:
  US11/040,242
• Publication Number:
  US 20060084606A1
• Time in Patent Office: 1,614 Days
• Field of Search: None
• US Class Current: 514/1.1
• CPC Class Codes: A61K 38/07 Tetrapeptides
• CPC Class Codes: A61K 38/08 Peptides having 5 to 11 amino acids A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61K 38/10 Peptides having 12 to 20 amino acids A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 39/06 Free radical scavengers or antioxidants
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07K 5/1019 with the first amino acid being basic

Abstract

The invention provides a method for reducing oxidative damage in a mammal, a removed organ, or a cell in need thereof. The method comprises administering an effective amount of an aromatic cationic peptide. The aromatic cationic peptide has (a) at least one net positive charge; (b) a minimum of three amino acids; (c) a maximum of about twenty amino acids; (d) a relationship between the minimum number of net positive charges (p_m) and the total number of amino acid residues (r) wherein 3p_m is the largest number that is less than or equal to r+1; (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p_t) wherein 3a or 2a is the largest number that is less than or equal to p_t+1, except that when a is 1, p_t may also be 1; and (f) at least one tyrosine or tryptophan amino acid.

Claims

1. A method for reducing oxidative damage in a mammal in need thereof, the method comprising administering to the mammal an effective amount of D-Arg-Dmt-Lys-Phe-NH₂ peptide.

2. The method according to claim 1, wherein the peptide is administered orally.

3. The method according to claim 1, wherein the peptide is administered topically.

4. The method according to claim 1, wherein the peptide is administered intranasally.

5. The method according to claim 1, wherein the peptide is administered systemically.

6. The method according to claim 3, wherein the peptide is administered intravenously.

7. The method according to claim 1, wherein the peptide is administered subcutaneously.

8. The method according to claim 1, wherein the peptide is administered intramuscularly.

9. The method according to claim 1, wherein the peptide is administered intracerebroventricularly.

10. The method according to claim 1, wherein the peptide is administered intrathecally.

11. The method according to claim 1, wherein the peptide is administered transdermally.

12. The method according to claim 11, wherein the transdermal administration is by iontophoresis.

13. The method according to claim 1, wherein the mammal is undergoing reperfusion.

14. The method according to claim 13, wherein the reperfusion is a treatment for ischemia.

15. The method according to claim 14, wherein the ischemia is due to stroke.

16. The method according to claim 1, wherein the mammal is suffering from sepsis.

17. The method according to claim 1, wherein the mammal is suffering from an inflammatory process.

18. The method according to claim 17, wherein the mammal is suffering from arthritis.

19. The method according to claim 1, wherein the mammal is suffering from diabetes.

20. The method according to claim 1, wherein the mammal is suffering from liver damage.

21. The method according to claim 20, wherein the liver damage is caused by a viral infection.

22. The method according to claim 20, wherein the liver damage is caused by a toxic agent.

23. The method according to claim 1, wherein the mammal is a human.

24. A method of reducing oxidative damage in a removed organ of a mammal, the method comprising administering to the removed organ an effective amount of D-Arg-Dmt-Lys-Phe-NH₂ peptide.